Dr David Samadi, chief robotic surgery at Lenox Hill Hospital, is a urologic surgeon specialized in laparoscopic, open, robotic and oncology surgeries. He was born and raised in a Jewish community in Iran. In 1982, during the Iranian revolution, he and his brother moved to London and Belgium six months later. His parents would not accompany them because of the Jewish traditions, and his small sister too was so young to be left under his care. Later, his parents arranged to move to a certain school in America where they had paid for their (David and his brother) stay. They stayed in a boarding school and graduated, joined high school and with the completion of high school David joined Stoney brook school of medicine and majored in biochemistry. He also studied in Montefiore Medical Centre where he studied general surgery.

He also has knowledge in urology acquired in Albert Einstein medical school, robotic prostatectomy from Henri Mondor Hospital in France and oncology, urology fellowship at Memorial Sloan Kettering Cancer Centre.#  Currently, Dr David Samadi is a great and magnificent surgeon and doctor who has specialized in prostate cancer. He performs an average of 15 prostate cancers surgeries per week to many people around the world. One of his patients was Mitt Romney, a previous presidential nominee of the Republican Party. Dr David Samadi announced that Romney was diagnosed with common and curable prostate cancer and following surgery, he was successfully treated. He is much experienced in prostate cancer treatment with robotic laparoscopic surgeries, the newest technological methods in the world of medicine.

He has performed many robotic prostate surgeries to over 7000 patients, and he stands to be the first prostate surgeon to perform the SMART technique in surgery using da Vinci system, a system designed to perform surgeries that are complex and involves fewer body invasions controlled by a surgeon. Dr David Samadi has won several awards including, New York super doctor in 2014, most empathetic doctor in 2011, Top Americas doctor 2008-2013, the America top doctor in the cancer field, selected by New York magazine as the best doctor in 2009-2012 and 2015. The magazine also selected him as the top 1251 doctors in the state in 2013-2014.In an interview with Idea mensch, he said that he believes that there is future in robotics and medical integration and he encourages technologist to venture more into the field.

How Oncotarget Is Remaining Relevant While providing Scientific data for medical practitioners

Oncotarget is a publishing company that publishes journals and distributes them on their online platform. Access to these publications is for free for all the websites clients. The releases are usually made on a weekly basis depending on the demand for the particular journals. Trending issues and topics at times determine the journal that will be published on Oncotargets website. The journals availed for its readers tend to cut across various disciplines hence the reason why the site is referred to as multidisciplinary. Over the years, Oncotarget has been striving to maximize the potential impact its published materials have on its audience while at the same time providing an insightful view to current issues within the scientific realm.

There has been an ongoing urgency by Oncotarget to abolish the boundaries within the biomedical specialties.With the leadership of the renowned scientists, Oncotarget has been providing researchers with journals that are aimed at contributing significantly to the development of sciences to one day achieve a life free from diseases.Oncotarget has been liaising closely with exemplary high-profile scientific indexes with the aim of providing all relevant scientific publications robustly to its clients. This has been well demonstrated by the collaboration between Oncotarget and IntegraGen.IntegraGen is a firm that has over the years specialized in the transformation of samples of biological data to genomic information and at times diagnostic equipment for Oncology.

Recently, news of the publishing of the analysis of tumor samples from patients who were undergoing the NEW EPOC clinical trial surfaced. Research carried out by IntegraGen show of a relationship between miR-31-3p expression and anti-EGFR treatment. There is the need to develop a tool that is capable of distinguishing patients who can benefit from this treatment option from those who can’t.As a business, Oncotarget doesn’t plan on being left behind with the 21st century’s technological wave. Currently, the firm is adopting new indexing algorithms aimed at the facilitation of dissemination of their scholarly Journals to relevant personnel within the sizeable medical research factions. Due to the increasing demand for Oncotargets journals, the company has shifted from publishing journals to their website one a week to the current rate of two Journals each week.

Dr. Clay Siegall Implements The Use Of Advanced Technolgy In Cancer Therapy

Research for the most suitable cancer medicine has been carried out since time in memorial, and Dr. Clay Siegall has been fully involved in the various scientific research processes that have been carried out by scientists, in the course coming up with a solution to the destructive ailment that has claimed more lives than any other disease. While undertaking different research processes, Dr. Clay realized that there was a great need to ensure that cancer patients are able to access medication that helps to lower the side effect of the ailment.

His previous life experience combined with the desire of ensuring that a final solution is developed to cure the complication, Dr. Clay Siegall helped to co-found Seattle Genetics. The research center was founded back in 1998, and it was originally established as a biotech company that would, in the end, help to spearhead research into different methods of curing cancer. Initially, the biotech company was a small medical facility startup, and most of the work was carried out using limited resources. Additionally, researchers at the organization were not as many compared to the current situation.

Through continuous effort and never giving up, Clay Siegall managed to prove to the world that his firm can successfully undertake in-depth research in cancer treatment and even come up with the most suitable medication. Seattle Genetics has managed to manufacture over 20 different types of drugs that have been distributed in the market to help in the treatment of cancer. Seattle Genetics, under the management of Clay Siegall, has managed to push through the challenges of the business world, and at the moment it is recognized as one of the largest biotechnology companies that helps to advance research on cancer treatment.

Clay Siegall studied medicine at the University of Maryland, and it is in the course of his studies that he realized the great passion that he had towards cancer research and treatment. He also realized that the current advancement in technology would help him achieve his dream of availing a suitable medication for treating various genetic related conditions.

Since his father had cancer, he loathed the manner in which chemotherapy was being administered at that time, Clay Siegall became motivated more than ever to ensure that the new methods are invented to help cancer patients access medication in a more humane manner.